Filtered By:
Condition: Heart Attack
Management: Healthcare Costs
Countries: USA Health

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 9 results found since Jan 2013.

Impact of cardiovascular disease on health care economic burden and resource utilization: a retrospective cohort study in adults in the United States with type 2 diabetes with or without stroke, myocardial infarction, and peripheral arterial disease
Conclusion: Having stroke, MI, or PAD was associated with increases in HCRU and costs in patients with T2DM. Although PAD was associated with smaller per patient increases in total healthcare costs than patients with T2DM + stroke/MI, the higher frequency of incident PAD may make it more costly than MI or stroke in a large population of patients with T2DM.PMID:36134459 | DOI:10.1080/03007995.2022.2125259
Source: Current Medical Research and Opinion - September 22, 2022 Category: Research Authors: Aaron King Jigar Rajpura Yuanjie Liang Yurek Paprocki Chioma Uzoigwe Source Type: research

Roche launches new ways to use their cardiovascular tests empowering clinicians to improve diagnosis and treatment of millions of people
Basel, 28 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced a series of five new intended uses for two key cardiac biomarkers using the Elecsys ® technology: high sensitive cardiac troponin T (cTnT-hs) and N-terminal pro-brain natriuretic peptide test (NT-proBNP). These gold standard biomarkers³ have proven to be successful in supporting cardiovascular disease management and can help clinicians diagnose heart attacks⁴ (cTnT-hs) and bett er manage heart failure⁵ (NT-proBNP). Roche ' s introduction of five new intended uses for these existing, globally accepted diagnostic solutions means more people could benef...
Source: Roche Media News - April 28, 2021 Category: Pharmaceuticals Source Type: news

Risk of Thromboembolic Events and Associated Healthcare Costs in Patients with Inflammatory Bowel Disease
ConclusionsPatients with IBD experienced greater rates of DVT and PE compared to patients without IMD; this elevated risk was associated with a substantial economic burden.
Source: Advances in Therapy - December 7, 2021 Category: Drugs & Pharmacology Source Type: research

Real-World Racial Variation in Treatment and Outcomes Among Patients with Peripheral Artery Disease
ConclusionsResults of this real-world study suggest that Black patients with PAD have higher disease severity at the time of diagnosis and are at increased risk of experiencing adverse outcomes following diagnosis.
Source: Advances in Therapy - March 6, 2023 Category: Drugs & Pharmacology Source Type: research